Tessera Therapeutics, the biotechnology company revolutionizing the genetic medicine space with its Gene Writing™ technology, has announced the appointment of Cynthia M. Patton as its General Counsel and Secretary. Ms. Patton brings an impressive 20+ years of legal and biotech experience to Tessera, having served as the General Counsel and Secretary at Verily and holding senior leadership positions at Amgen.
We are delighted to welcome Cynthia to Tessera Therapeutics as our General Counsel! With decades of experience in the healthcare and biotech industries, she has played a key role in advancing novel solutions and groundbreaking disciplines in healthcare. Cynthia’s expertise will be invaluable as Tessera embarks on its mission to develop potentially curative genetic medicines and bring them to patients.
Cynthia Patton is thrilled to be joining the Tessera Therapeutics team at a pivotal moment in the company’s development. With the revolutionary Gene Writing technology platforms that they utilize, Tessera is paving the way for precise therapeutic corrections to treat the root causes of many diseases, which could potentially make a life-changing impact on patients. She is looking forward to taking part in this groundbreaking journey.
Cynthia has an impressive career history, most recently having served as General Counsel and Secretary at Verily Life Sciences, the healthcare subsidiary of Alphabet. She was responsible for managing a team of 160 colleagues as Senior Vice President and Chief Compliance Officer for Amgen’s global privacy, trade and healthcare compliance organizations.
Prior to joining Verily, Cynthia held various positions at Amgen, including Vice President, Law, with responsibility for commercial legal activities in the U.S. and lead commercial lawyer for both the oncology and inflammation business units. Before Amgen, Cynthia worked as general counsel of SCAN Health Plan, a California Medicare advantage plan, and spent several years at law firms specializing in healthcare, corporate and securities law.
Cynthia is an active leader in the community, currently serving on the boards of Organon, Inc., the NAACP Legal Defense Fund, the Ethics and Compliance Initiative, Martin Luther King, Jr. Community Hospital in Los Angeles, the Los Angeles Music Center, Vassar College, New York University School of Law’s Program on Corporate Compliance and Enforcement, and The National Association for Law Placement Foundation.
She recently served as the board chair of the Amgen Foundation, a position she held with distinction. Cynthia’s commitment to making a positive impact in the world has been unwavering throughout her career.
Cynthia achieved her educational goals by graduating with a J.D. from George Washington University and a bachelor’s degree from Vassar College. With her hard work and dedication, she was able to open the door to many exciting opportunities.
About Tessera Therapeutics
Tessera Therapeutics is revolutionizing genetic medicine with its revolutionary Gene Writing™ technology. By utilizing multiple technology platforms, scientists and clinicians can now write therapeutic messages directly into the human genome, with the potential to cure diseases at the source.
This ground-breaking technology not only allows for the correction of single nucleotides, but also enables the insertion or deletion of short DNA sequences, and even the writing of entire genes into the genome. Founded in 2018 by Flagship Pioneering, Tessera Therapeutics is on a mission to bring the promise of genetic medicine to life.